| payload |
{"created_at":"2026-04-15T02:18:53.247 {"created_at":"2026-04-15T02:18:53.247056+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:019d8699d1fa16d1","evidence_event_ids":["evt_35aa6ab00b35"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001950047-26-003436.txt","as_of":"2026-04-15T02:18:53.247056+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001950047-26-003436.txt","company":"Vera Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001950047-26-003436.txt","article_chars":1711,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_d31e78647ea545e8","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001950047-26-003436.txt","content_type":"text/plain","enriched_at":"2026-04-15T04:19:21.775992+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001950047-26-003436.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001950047-26-003436.txt","source_event_id":"evt_35aa6ab00b35","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"144","fp":"36325a85e9471634","kind":"sec_filing","published_at":"20260414","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-14","2026-02-20","2026-02-23","2026-01-09"],"entities":[{"asset_class":"equity","name":"Vera Therapeutics, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"equity","name":"Marshall Fordyce","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"Morgan Stanley Smith Barney LLC","relevance":"medium","symbol":"","type":"broker"}],"event_type":"listing","information_gaps":["The text does not explicitly state the total number of shares to be sold in a clearly labeled way; it shows numeric blocks but without field labels in the provided excerpt.","The signal is categorized as \u201clisting,\u201d but the document is Form 144 (typically related to resale/disposition); the provided text does not include an explicit narrative describing the purpose beyond the Form 144 structure.","No prior known state/delta is provided in the prompt, so \u201cwhat changed vs prior known state\u201d cannot be determined from the supplied information alone."],"key_facts":["SEC accession number: 0001950047-26-003436.","Conformed submission type: Form 144.","Filed as of date: 20260414; date as of change: 20260414.","Subject company/issuer: Vera Therapeutics, Inc. (CIK 0001831828; SEC file number 001-40407).","Reporting owner: Marshall Fordyce (listed as Director/Officer).","Document includes entries referencing \u201cRestricted Stock Units\u201d and \u201cCommon\u201d with multiple dates (e.g., 02/20/2026, 02/23/2026, 04/14/2026, 01/09/2026) and quantities/values shown in the text.","Broker line includes \u201cMorgan Stanley Smith Barney LLC\u201d with address \u201c1 New York Plaza 8th Floor New York NY 10004\u201d.","Company business address listed as 2000 Sierra Point Parkway, Suite 1200, Brisbane, CA 94005."],"numeric_claims":[{"label":"Form 144 accession","value":"0001950047-26-003436"},{"label":"Filed as of date","value":"20260414"},{"label":"EIN","value":"812744449"},{"label":"SEC file number","value":"001-40407"},{"label":"CIK (issuer)","value":"0001831828"},{"label":"CIK (reporting owner)","value":"0001859453"},{"label":"Quantity/value shown (first numeric block)","value":"22951"},{"label":"Quantity/value shown (second numeric block)","value":"1003188.21"},{"label":"Quantity/value shown (third numeric block)","value":"71355667"},{"label":"Quantity/value shown (later numeric block)","value":"16925"},{"label":"Quantity/value shown (later numeric block)","value":"710577.51"}],"primary_claim":"On 2026-04-14, Vera Therapeutics, Inc. filed SEC Form 144 (accession 0001950047-26-003436) for reporting owner Marshall Fordyce.","relevance_score":0.45,"sentiment":"neutral","source_quality":"medium","summary":"Vera Therapeutics, Inc. filed a Form 144 on 2026-04-14. The filing is associated with reporting owner Marshall Fordyce and relates to common stock shares/RSUs with dates and quantities shown in the document.","topics":["SEC Form 144","insider/director sale/disposition","restricted stock units","common stock","Vera Therapeutics"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 144 \u00b7 Vera Therapeutics, Inc. \u00b7 Filed 20260414","ticker":"VERA","tickers":["VERA"],"title":"VERA filed 144","url":"https://www.sec.gov/Archives/edgar/data/1831828/0001950047-26-003436.txt"}}... |